← Eichor
Study identifier: NCT06645379 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Application of Platelet-rich Plasma (PRP) in Reproductive Medicine

Condition: Premature Ovarian Insufficiency · Intrauterine Adhesion · Poor Ovarian Response  ·  Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

PhaseNA
Planned participants300
Who can joinFemale, 18 Years to 50 Years
Healthy volunteersNo

About this study

Female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. In reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. These five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.

This description comes directly from the study's public registry record.

Talk to the study team

Youhua Lai  ·  +86 15925977413  ·  tj_lyh1@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Fourth Affiliated Hospital of Zhejiang University School of MedicineYiwu, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06645379